“We plan to perform a further analysis evaluating the efficacy and safety of brodalumab in patients across specific racial/ethnic subgroups, including black, Asian, and white patients with psoriasis,” Dr. McMichael said. Additionally, a population-based study to investigate treatment patterns in patients with psoriasis across racial and socioeconomic groups could also shed light on how patients with skin of color manage their psoriasis, she added.
Dr. McMichael’s disclosures include having been an investigator for Allergan, Incyte, and Samumed and a consultant to Aclaris, Galderma, IntraDerm, Johnson & Johnson, Merz, Pfizer, and Procter & Gamble.
dermnews@frontlinemedcom.com
SOURCE: McMichael A et al. ODAC 2018.
